Category: Corona Virus Vaccine

Page 65«..1020..64656667..7080..»

UofL Health marks 3-years after first staff members receive COVID-19 vaccine – WLKY Louisville

December 16, 2023

UofL Health marks 3-years after first staff members receive COVID-19 vaccine

Updated: 5:19 PM EST Dec 14, 2023

It's been three years since the first people in Kentucky received the COVID-19 vaccine.On Dec. 14, 2020, UofL Health's Chief Medical Officer Jason Smith and four of his colleagues received their first dose of the Pfizer vaccine. At that time, the hospital system was treating hundreds of patients for the coronavirus.The arrival of the vaccine demonstrated the best of medicine and our commonwealths collaborative spirit, Smith said. For the first time, we had a tool to minimize the spread of COVID-19 in a significant way.Since then, UofL Health has administered more than 170,000 doses of the vaccine, including first, second, third and fourth shots. UofL Health currently has 30 patients who have COVID-19, four of whom are in the intensive care unit.

It's been three years since the first people in Kentucky received the COVID-19 vaccine.

On Dec. 14, 2020, UofL Health's Chief Medical Officer Jason Smith and four of his colleagues received their first dose of the Pfizer vaccine.

At that time, the hospital system was treating hundreds of patients for the coronavirus.

The arrival of the vaccine demonstrated the best of medicine and our commonwealths collaborative spirit, Smith said. For the first time, we had a tool to minimize the spread of COVID-19 in a significant way.

Since then, UofL Health has administered more than 170,000 doses of the vaccine, including first, second, third and fourth shots.

UofL Health currently has 30 patients who have COVID-19, four of whom are in the intensive care unit.

Link:

UofL Health marks 3-years after first staff members receive COVID-19 vaccine - WLKY Louisville

CDC warns of ‘urgent need’ to increase vaccinations for COVID-19, other respiratory illnesses – UPI News

December 16, 2023

Dec. 14 (UPI) -- Healthcare providers throughout the United States are in for a rough winter if immunization rates against COVID-19 and other respiratory illnesses do not increase, the CDC warns.

The Centers for Disease Control and Prevention on Thursday warned healthcare providers of an "urgent need" to increase vaccination rates against COVID-19, influenza and respiratory syncytial virus (RSV).

According to the CDC, low vaccination rates and an ongoing increase of national and international cases could lead to an increased strain on the capacity of healthcare organizations in the coming weeks.

In the past four weeks, hospitalizations among all age groups increased 200% for influenza, 51% for COVID-19 and 60% for RSV, according to the CDC.

"Influenza, COVID-19 and RSV can result in severe disease, especially among unvaccinated persons," the organization said in a statement. "Infants, older adults, pregnant people and people with certain underlying medical conditions remain at increased risk of severe COVID-19 and influenza disease. Infants and older adults remain at highest risk of severe RSV disease; it is the leading cause of infant hospitalization in the United States."

COVID-19 vaccination rates are low this winter, with the CDC reporting 17.2% of adults having received the latest booster, along with 7.7% of children under 18 and 9.6% of pregnant people, as of Dec. 2.

Seasonal flu vaccination coverage is low across all age groups as well. As ofNov. 2 the CDC reported 7.4 million fewer doses administered to adults compared to the same time last year.

The CDC said key reasons for low vaccine uptake this year include lack of provider recommendation, concerns about unknown side effects, occurrences of mild side effects and lack of time or forgetting to get vaccinated.

The organization urged health care providers to administer influenza, COVID-19, and RSV immunizations now to patients, if recommended, and to use all available tools to increase immunization rates.

The CDC also recommended people take everyday preventive measures such as washing hands, covering coughs and sneezes, wearing a mask, and staying home when sick.

See the original post here:

CDC warns of 'urgent need' to increase vaccinations for COVID-19, other respiratory illnesses - UPI News

PET/CT shows impact of different COVID-19 vaccines – AuntMinnie

December 16, 2023

The type of COVID-19 vaccine and the time interval between vaccination and PET/CT scans are key factors in minimizing false interpretations in cancer patients, according to research published December 9 in Scientific Reports.

The study is the first to examine systemic response changes in patients in correlation to time after COVID-19 vaccination using three different vaccines, and may help minimize dilemmas for clinicians, wrote first author Tina Nazerani-Zemann, MD, of the Medical University of Graz in Austria, and colleagues.

Different vaccines cause different system metabolic changes. The knowledge of vaccine type, the time interval between vaccination and PET/CT scan is essential, especially in therapy evaluation, the group noted.

Previous studies have shown that COVID-19 vaccines can cause axillary lymphadenopathy and that this may mimic activity typically associated with metastasis in oncologic patients, the authors explained.

As the vaccination program continues, we encountered increased F-18 FDG-activity not only in axillary lymph nodes ipsilateral to the injection site but also in other organs, the authors noted.

To further elucidate cancer patient reactions to COVID-19 vaccines, the authors aimed to show any systemic metabolic changes after vaccination with three different vaccines in relation to time.

The group collected data on 220 eligible vaccinated cancer patients (127 with the Pfizer-BioNTech vaccine, 61 with the Moderna, and 32 with AstraZeneca vaccines) who underwent F-18 FDG-PET/CT scans. Of these, 71 patients also underwent a pre-vaccination scan. Most of the patients (n=175 did not receive any therapy related to their diagnosis at the time of the PET/CT scan.

The researchers evaluated the exams from day 1 to day 135 after different vaccinations and compared the standardized uptake value (SUVmax) ratio of tracer activity of axillary lymph node to reference organs in all patients, with differences in tracer activity dynamics explored based on the three different vaccines.

A 73-year-old woman with a suspicious lung nodule was referred to our division for F-18 FDG PET/CT exam. She was vaccinated four days before PET/CT. The lung nodule did not show any pathological FDG uptake; however, high tracer activity was detected on her right arm, where she was injected, and multiple hypermetabolic lymph nodes in the right axilla (arrows). Moreover, PET/CT showed high tracer activity in the liver (black arrows), spleen (triangular arrows), and bone marrow (small triangular arrows) as the result of systemic immune response after vaccination. The tracer defect in the liver was due to the known cyst. (A) fusion scan, (B) PET, (C) maximum intensity projection. Image courtesy of Scientific Reports.

SUVmax of ipsilateral lymph node activity was slightly higher (mean, 3.00) in patients who received the Moderna vaccine than the BioNTech/ Pfizer-BioNTech (mean, 2.69) and AstraZeneca (mean, 2.61), according to the findings.

This FDG activity in axillary lymph nodes showed a steady decrease in all patients after Pfizer-BioNTech vaccinations. Ten days after vaccination, the FDG uptake was at its highest activity, and 70 days after vaccination, the FDG activity was not different from the background activity of the tracer in the axillary region, the researchers reported.

This result also applies to other two vaccines, the group wrote.

However, the authors highlighted several differences in terms of the timing of this activity. The highest peak of activity occurred in the fourth week for Moderna vaccinations and at the 10th day for AstraZeneca vaccinations.

Finally, the researchers noted that there was no significant changes of FDG tracer activity in other reference regions (the mediastinum, spleen, and bone marrow) between the three vaccinations.

Ultimately, numerous studies suggest increased activity in local sites and ipsilateral axillary lymph nodes in F-18 FDG PET/CT scans after COVID-19 vaccination, yet correctly interpreting these changes remains a challenge, the authors noted.

Our study underscores the significance of changes in 2-[F-18] FDG PET/CT scans in lymph nodes and reference organs after vaccination and highlights the importance of this information in the interpretation of PET/CT in vaccinated patients, the group concluded.

The full study is available here.

Continued here:

PET/CT shows impact of different COVID-19 vaccines - AuntMinnie

China detects seven cases of new Covid-19 subvariant JN.1. What are symptoms? – Hindustan Times

December 16, 2023

China has detected seven infections of the Covid subvariant JN.1, news agency Reuters has reported, citing the country's national disease control and prevention administration on Friday.

The authorities said the prevalence level of JN.1 is currently "very low" in the country, but added that it cannot rule out the possibility of it becoming the dominant strain in China due to factors including imported cases.

According to the US Centers for Disease Control and Prevention (CDC), JN.1, a variant of the virus that causes COVID-19, is a closely related offshoot of the variant BA.2.86.

As per the CDC, there is only a single change between JN.1 and BA.2.86 in the spike protein.

JN.1 was first detected in the United States in September 2023.

As of December 8, the public health agency of the United States projects that the variant JN.1 makes up between 1529% of the total cases in the United States.

(The) CDC projects that JN.1 will continue to increase as a proportion of SARS-CoV-2 genomic sequences. It is currently the fastest-growing variant in the United States, the public health agency of the US said.

According to a report in The Times of India, the new coronavirus variant was first detected in Kerala on December 13.

The latest data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG) also confirmed its presence in Kerala.

National Indian Medical Association COVID Task Force's co-chairman Dr Rajeev Jayadevan said that JN.1 may be a contributing factor to the recent surge in India's Covid cases, which currently stands at 1,296.

As per the CDC, It is not currently known whether the JN.1 variant of coronavirus produces different symptoms from other variants. In general, the symptoms of COVID-19 tend to be similar across variants.

The types of symptoms and how severe they are usually depend more on a persons immunity and overall health rather than which variant causes the infection, the CDC said.

While the severity of JN.1 is yet to be figured, the US CDC has said that thecontinued growth of JN.1 suggests that it is either more transmissible or better at evading our immune systems.

At this time, there is no evidence that JN.1 presents an increased risk to public health relative to other currently circulating variants, it said. There is no indication of increased severity from JN.1 at this time. Updated COVID-19 vaccines are expected to increase protection against JN.1, as they do for other variants.

Follow the latest breaking news and developments from India and around the world with Hindustan Times' newsdesk. From politics and policies to the economy and the environment, from local issues to national events and global affairs, we've got you covered....view detail

Read the rest here:

China detects seven cases of new Covid-19 subvariant JN.1. What are symptoms? - Hindustan Times

New COVID-19 variant spreads as Kansans travel for the holidays – Kansas Reflector

November 25, 2023

TOPEKA Health officials warn travelers to watch out for a highly contagious new COVID-19 variant when making plans this month.

During a Tuesday update on COVID-19 cases, the University of Kansas Health System reported treating 24 COVID-19 patients this week. Dana Hawkinson, director of infection prevention and control at the system, said the slight increase up from 16 cases the week prior, showed the virus is still spreading in Kansas communities.

We know the virus is circulating out there, so everybody be careful and have a plan when you are traveling and going to visit families and friends, Hawkinson said.

The Centers for Disease Control and Prevention reported a spike in a new subvariant, the HV.1 COVID-19 variant. For the week ending Nov. 11, the latest national data shows COVID-19 hospitalization rose about 8.6% and COVID-19-related deaths rose about 9.1%. During that same time frame, 16, 239 people were hospitalized due to the virus.

Andrea Garcia, vice president of science, health and medicine at the American Medical Association, said there has been a seasonal spread.

We have a new COVID variant called HV.1 that we do need to keep an eye on, Garcia said. Its just been a few short weeks and HV.1 has become the variant responsible for most COVID cases here in the U.S.

Kansas COVID-19 cases havent been widely documented by the state since the end of the federal COVID-19 emergency declaration. Since the CDC stopped tracking cases of infection, hospitalizations are now the primary indicator of COVID-19 spread.

While cases in general remain low, Montana, Wyoming, Nebraska and Kansas have documented rising clusters of cases. In Kansas, CDC data shows around 197 new weekly hospitalizations.

See more here:

New COVID-19 variant spreads as Kansans travel for the holidays - Kansas Reflector

Therapeutic plasma exchange in the treatment of COVID-19 induced … – BMC Infectious Diseases

November 25, 2023

In our study, a statistically significant improvement of clinical (SpO2 and PaO2/FiO2 ratio) and biological (Lymphocytes, CRP, IL-6, Ferritin, D-dimers, Fibrinogen) parameters was attributed to the use of therapeutic plasma exchange in the first group. Additionally, a statistically significant difference was observed comparing clinical (SpO2 and PaO2/FiO2 ratio) and biological (WBC, D-dimers, Fibrinogen) between both groups included in this study, as well as a higher extubation rate, a lower ICU length of stay and mortality in group 1.

Beyond its pulmonary tropism, COVID-19 is a systemic disease with multi-organ involvement attributed to an excessive immune response to the virus [20, 21]. In fact, this hyperinflammatory induced state has been well documented and corresponds to the "cytokine storm" syndrome previously described in various conditions [8, 9].

Serum cytokine levels that are elevated in patients with COVID-19-associated cytokine storm include interleukin-1, interleukin-6, IP-10 (Interferon gamma-induced protein 10), TNF (Tumor Necrosis Factor), interferon-, MIP-1 and 1 (Macrophage Inflammatory Protein-1 Alpha and 1 Beta) proteins, and VEGF (Vascular Endothelial Growth Factor) [10, 21]. Higher levels of interleukin-6 are strongly associated with shorter survival [11]. Circulating activated CD4+and CD8+(Cluster Of Differentiation 4 and 8) T cell and plasmablast levels are also increased in COVID-19 [12].

In addition to elevated systemic cytokine levels and activated immune cells, several clinical and laboratory abnormalities, such as elevated CRP and d-dimer levels, hypoalbuminemia, renal dysfunction, and effusions, are also observed in COVID-19. These organ failures and biological abnormalities reflect the degree of hyperinflammation and tissue damage and can predict the prognosis of COVID-19 [13].

Pre-existing comorbidities such as hypertension, diabetes, and obesity are associated with more severe forms of COVID-19 [14], perhaps due to the pre-existing chronic inflammatory state or a lower threshold for the development of organ dysfunction due to the immune response [5].

Naturally, therapies targeting hyperinflammation, such as immunosuppressants [15], and therapeutic plasma exchange therapy (given their proven role in blood purification by eliminating high molecular weight circulating substances and restoring homeostasis in many dysregulated biological pathways [16]), have a valuable place in the therapeutic arsenal against COVID-19.

In a multicenter case-control study was conducted by Gucyetmez et al. [17] to determine the effectiveness of TPE in patients with COVID-19 admitted to five ICUs in Turkey. The patients were divided into two groups: group 1 consisted of 18 patients who received three consecutive TPE sessions, and group 2 consisted of 35 patients who only received standard therapeutic protocol. The mean SpO2 in group 1 was 917% vs. 895% in group 2. The same study also reported a mean pre-TPE WBC count of 9.084.1103/L compared to a mean post-TPE WBC count of 9.143.5103/L. To date, the study by Gucyetmez et al. and ours are the only ones to have included SpO2 and WBC count as variables to study the effectiveness TPE in COVID-19.

Similarly, to our findings, a randomized control trial including 87 patients divided into two groups [18], depending on who benefited from TPE on top of the standard therapeutic protocol or just the latter, and in which significant improvement in PaO2/FiO2 ratio, CRP, IL-6, Ferritine, and D-dimers were noted before and after TPE sessions. The same study reported better clinical and biological parameters in the intervention group comparted to the control group.

While the efficiency of TPE has extensively documented, the diversity of methods used by each center has been well documented, particularly in the literature review conducted by Krzych et al. [6] and later by Beraud et al. [19], the latter of which included 34 articles (1 randomized controlled trial, 4 casecontrol studies, 15 case series, and 14 case reports, totaling 267 patients treated with plasma TPE).

We highlighted three major differences. First, the number of sessions varied from 1 to 9 sessions depending on the case series in question. Second, there was a variability in the choice of replacement fluid, with Fresh Frozen Plasma (FFP) being the most commonly used, followed by 5% albumin. Finally, there was a predominance of regional citrate anticoagulation (RCA) [6, 19].

In the absence of guidelines regarding the practical aspects of TPE and following the departments procedural habits, we opted for a number of 5 consecutives TPE sessions using FFP as a substitution fluid and heparin for anticoagulation given that RCA is not available. The therapy was provided to patients based on the informed consent of either the patient or a proxy, and also based on the therapys availability given the limited number of machines, consumables, and FFP.

Taking into account the therapys procedural diversity, a multinational team of the International Society of Blood Transfusion (ISBT) conducted a literature review relying on the recommendations of the American Society for Apheresis (ASFA) to formulate preliminary clinical practice recommendations related to the performance of plasma exchanges in COVID-19 [22], which concluded up to the date of its publication that the use of TPE in COVID-19-induced cytokine storm is categorized as Class III, Grade 2B, meaning that its optimal role is not established, and that the quality of evidence evaluated at that time supported only a weak overall recommendation for this approach, indicated in critically-ill COVID-19 patients with virtually no absolute contraindications, initiated early in the disease progression, using FFP or ideally convalescent plasma for substitution, and RCA for anticoagulation. The recommended exchange volume is 1 to 1.5 times the patients TPV (Total Plasma Volume), for virtually as many sessions as necessary.

The results of our cohort are in line with those widely reported by several studies already in the literature, advocating for the effectiveness of plasma exchange in COVID-19, especially in severely ill patients requiring ICU care.

The COVID-19 pandemic proved to be a unique experience, opening the door to an unlimited potential of research and experimentation. While our study could have been better led, with more clinical and biological parameters monitored, it offers ad significant sample size, with valuable results.

That said, further studies are needed to first describe more specifically and closely delineate the clinical-biological spectrum of the cytokine storm induced by COVID-19, particularly its often-neglected extrapulmonary manifestations, but also to support the safety and efficacy of plasma exchange in COVID-19.

In this sense, it would be preferable to evaluate the use of plasma exchange alone, or in combination with other therapies, for COVID-19 patients in the context of prospective, randomized, and controlled clinical trials. This approach could yield fruitful results in saving lives and paving the way for future consideration of plasma exchange in similar diseases.

Our study has a number of strengths including a specific focus on the use of TPE in critically-ill patients, joining only a limited number of studies published to this day, as well as comparative approach comparing outcomes before and after TPE sessions within Group 1 and conducting an event-based comparison between both groups, enhancing the depth of the analysis. This Event-Based Comparison provides a meaningful endpoint, aligning with practical clinical outcomes. This study also carries certain weaknesses such as its retrospective and single-center design. Also, a longitudinal data analysis comparing parameters and outcomes at various time points, accounting for individual variations would have been more informative, specifically on the efficiency of TPE with less than 5 sessions.

Here is the original post:

Therapeutic plasma exchange in the treatment of COVID-19 induced ... - BMC Infectious Diseases

Impacts of COVID-19 pandemic through decomposition of life … – Nature.com

November 25, 2023

In the analysis, we distinguished four potential types of places of death: deaths at home, in medical facilities (hospitals or other medical facilities), in facilities of social care (social care houses), or at other places. Most CVDs deaths occurred in medical facilities (more than 50% in all the studied years). Before the pandemic, around 26% of CVDs deaths occurred at home annually. During the pandemic, this proportion increased to more than 30% in 2021. COVID-19 deaths occurred mostly (around 90%) in medical facilities (Table 1).

For the studied years, Table 2 (pre-pandemic development) and Table 3 (development during the pandemic) show the annual changes in life expectancy at birth and contributions of deaths from CVDs and COVID-19 according to places of death.

Life expectancy at birth is a summary measure of the current health status of the population under study. If the level of mortality increases, life expectancy decreases, and vice versa. According to contributions of particular causes of death, if mortality from the selected cause increases, the contribution of this cause to a change in life expectancy is negative, i.e., worsening of mortality from any cause of death negatively contributes to a life expectancy change.

Between the years 2019 and 2020, the life expectancy at birth decreased by almost a year. The second pandemic year brought a further decrease in life expectancy, by more than a year (1.03years). The year 2022 was the first year since the pandemic during which life expectancy increased again (+1.76years).

Before the pandemic, a decrease in CVDs mortality contributed significantly to the growth in life expectancy (Tables 2 and 3). Between the years 2017 and 2018, the contribution of CVDs was even higher than the overall increase in life expectancy (+0.14 and+0.17years; the positive contribution of CVDs was moderated by a mortality increase from other causes of death).

A significant change was observed in the first pandemic yearthe contribution of CVDs was negative (0.18years; mortality from CVDs increased) and supported the negative development of life expectancy in 2020. Thus, the higher level of CVDs mortality in 2020 contributed to the overall reduction in life expectancy at birth (Table 3).

In the second year of the pandemic, there was a reversal. Despite the COVID-19 pandemic peaking in 2021, the positive development in CVDs mortality was observable. Improvement in CVDs mortality helped to moderate the life expectancy decrease caused mostly by COVID-19. In 2022, also CVDs contributed significantly (+0.15years) to the overall rapid increase in life expectancy (Table 3).

The next part of Tables 2 and 3 describes the contribution of COVID-19 to life expectancy changes. In the first year of the pandemic, COVID-19 mortality led to a reduction in life expectancy at birth by 0.74years. The second pandemic year was even worse, and COVID-19 itself led to a decrease in life expectancy by 1.19years. In the final year of the pandemic, mortality from COVID-19 decreased again.

Tables 2 and 3 show also the contribution of CVDs and COVID-19 mortality according to places at death. Most of the negative contribution of COVID-19 was due to deaths in medical facilities because most of the COVID-19 deaths occurred in hospitals (9092%). Vaccination against COVID-19 was initiated during the first months of 2021, preferably from the oldest age groups, or in facilities of social care. This is reflected in the positive contributions of COVID-19 mortality at facilities of social care to life expectancy change between 2020 and 2021.

The situation was different according to CVDs. Before the pandemic, contributions of CVDs mortality were around zero at all places except for medical facilities where decreasing CVDs mortality helped to increase the overall life expectancy. Whereas the CVDs mortality rates in hospitals improved until 2019, CVDs mortality rates out-of-medical facilities were almost stable (Table 2).

In the first pandemic year (2020), the negative contribution of CVDs mortality to the overall change in life expectancy was mainly due to higher CVDs mortality at home and in social care houses. At these two places, the level of CVDs mortality worsened, i.e., the number of CVDs deaths at home or social care houses increased the most. In 2021, CVDs mortality in social care houses and in medical facilities improved and helped to decrease CVDs mortality. The contribution of CVDs mortality at home was already close to zero, but still negative (supporting the decrease in life expectancy). In the final pandemic year, 2022, contributions of CVDs mortality regardless of the place of death were positive again (Table 3).

Figure1 shows the overall development of CVDs health care provision and mortality in Czechia in time, i.e., development of the studied time seriesCVDs hospitalizations (panel A), CVDs ambulant care (B), CVDs deaths in medical facilities (C), at home, and in facilities of social care (D). The monthly data are adjusted for the length of particular months in the period January 2018December 2022. Clearly, in the time series, a strong seasonal pattern can be seen (see Fig.2Seasonal component of time series decomposition). There is also a long-term decreasing trend in some seriesabove all CVDs hospitalizations (Fig.1A) or CVDs deaths in medical facilities (Fig.1C). This trend started already before the pandemic. On the other hand, there was an increase in CVDs ambulant care before the pandemic, which was interrupted in 2020 (Fig.1B). The number of CVDs deaths at home or in facilities of social care had almost a stable trend during the studied period, however, with high variability (Fig.1D). The visible peak at the end of 2020 could be considered as an indirect effect of the pandemic and will be discussed later in more detail. The significant exceptional increases or decreases in the development are depicted in Fig.3.

Source:14,15,16, authors calculation, output of the SAS software, version 6.4.

Time series of monthly data adjusted for the length of particular months, January 2018December 2022, CVDs hospitalizations (A), CVDs ambulant care (B), deaths in medical facilities (C), deaths at home and facilities of social care (D), Czechia.

Source:14,15,16, authors calculation, output of the SAS software, version 6.4.

Seasonal component of time series decomposition (1=average month corresponding to the overall trend of the time series), January 2018December 2022, CVDs hospitalizations (A), CVDs ambulant care (B), deaths in medical facilities (C), deaths at home and facilities of social care (D), Czechia.

Source:14,15,16, authors calculation, output of the SAS software, version 6.4.

Irregular component of time series decomposition (1=average month corresponding to the overall trend and seasonal factor of the particular month of the time series), January 2018December 2022, CVDs hospitalizations (A), CVDs ambulant care (B), deaths in medical facilities (C), deaths at home and facilities of social care (D), Czechia. Note: the dotted horizontal line at value one represents the reference level corresponding to an expected values of the time series for a particular month reflecting the trend and seasonal pattern.

The seasonal patterns (Fig.2) of the analysed series are stable in time (in contrast to more traditional approaches to time series seasonal decomposition, the used X-13 methodology potentially allows for moving seasonal components, slightly developing in time). Values around one represent an average month within a year. There is a traditional decrease in the number of CVDs hospitalizations as well as CVDs ambulant care during the summer and in December each year (by some 20%, represented by values around 0.8 in Fig.2). On the other hand, the peak of CVDs mortality repeats annually in the first quartile of the year (regardless of the place of death).

Figure3 shows the irregular component of the time series decomposition. It reveals the unexpected or exceptional changes in the studied time series. Values around one correspond to expected values of the time series for a particular month reflecting the trend and seasonal pattern. For CVDs health care, there is an abrupt drop in March and April 2020, in both time series the values of provided health care decreased in those months to almost 70% of expected values (values around 0.7 in Fig.3). This decrease is partially replaced by an exceptional increase in CVDs ambulant care during the summer of 2020, however, this increase was only about 20%. Another decrease in the number of CVDs hospitalizations as well as ambulant care was observable at the end of 2020. The observable decrease in CVDs hospitalizations at the very end of 2022 may correspond to the strong flu epidemics at that time.

Several peaks of CVDs mortality were seen during the studied years. The first peak occurred at the beginning of 2018. This likely corresponds to weather conditions and flu epidemics typical for this time of the year, however stronger in the studied year. Except for these smaller or bigger peaks repeating similarly (however, not strictly regularly so as to be included in the seasonality pattern) every year during the first months (reinforcing the long-term seasonal effect), there are no strong deviations from random fluctuations around one (corresponding to average months). The change occurred with the start of the pandemicin April 2020, there was an increase in the number of CVDs deaths at home by 10% in comparison to an average April in the studied years and an increase of almost 9% in deaths in facilities of social care. This corresponds to the observed decrease in CVDs health care or hospitalization in March or April of that year. For the sake of completeness, this time, from March 12th to May 17th, 2020, a State of Emergency was declared in Czechia24.

An even more significant increase in CVDs deaths occurred, however, at the end of 2020above all in October 2020 (increase by 12% in medical fac., 15% at home, and 29% in facilities of social care) and November 2020 (increase by 45% in facilities of social care, the increase in deaths at home or in medical facilities was around 23%). At this time, the next State of Emergency was declared in Czechia in the period from October 5th, 2020, to February 14th, 202124.

The last exceptional increase in deaths at home occurred in November 2021 by 14% and at medical facilities (hospitals) in December 2022 by 12% which likely corresponds to an already mentioned flu epidemic.

More:

Impacts of COVID-19 pandemic through decomposition of life ... - Nature.com

Post-COVID-19 Sleepiness Could be Undiagnosed Obstructive … – MD Magazine

November 25, 2023

Post-COVID-19 symptoms like daytime sleepiness, fatigue, and memory/concentration problems may be because of reduced sleep efficiency and undiagnosed obstructive sleep apnea, a new study found.1

People who have COVID-19 have reported experiencing symptoms, such as chronic pain, brain fog, shortness of breath, chest pain, and intense fatigue, for either weeks, months, or years after a SARS-Cov-2 infection. One 2021 study found 76% of 1655 patients with COVID-19 had persistent symptoms for 6 months after leaving the hospital. Symptoms included respiratory and cardiac symptoms, as well as neurological symptoms63% had fatigue, 26% had sleep difficulties, 11% had smell disorders, 7% had taste disorders, 6% had dizziness, and 2% had myalgia and headache.

A U.S. Household Pulse Survey, conducted by the Census Bureau and National Center for Health Statistics, found the percentage of participants with lingering or new symptoms post-COVID dropped to 11% in January 2023 from 19% in June 2022. The decline reason remains unknown. A Yale Medicine cardiologist, Erica Spatz, MD, MHS, believed the decline could be due to more people getting vaccinated, as well as milder variants.2

A new single-center retrospective study, led by Katja Menzler, from the department of Neurology at Philipps-University Marburg in Marburg, Germany, aimed to evaluate the polysomnographic results of post-COVID-19 patientsand thus diagnosing potential sleep disorders. The study referred to the condition of experiencing lingering COVID-19 symptoms for > 12 weeks as post-COVID syndrome. Though, the Centers for Disease Control (CDC) refers to experiencing symptoms for > 4 weeks as Post-COVID Conditions.3 Risk factors linked to post-COVID syndrome include female, sex, middle age, other chronic diseases or psychiatric diseases, and the severity of the infection.

The study included 34 patients with post-COVID syndrome between March 2021 and December 2022. The sample had a mean age of 45.5 12.1 years, as well as 27 females and 7 males. All patients reported new-onset fatigue and sleepiness after SARS-CoV2 infection. Patients underwent polysomnography between January 2021 and October 2022.

After getting infected by COVID-19, one patient had excessive snoring and witnessed apnea;, another patient had preexisting snoring without apnes (after the infection snoring had increased), 4 patients had occasional snoring, 3 patients had previous asthma, and one patient had a history of pulmonary.

The polysomnography revealed 26% (n = 9) had a sleep latency of < 30 minutes, 35% (n = 12) had a total sleep time of < 6 hours, and 50% (n = 17) had a reduced sleep efficiency of < 80%. None of the patients demonstrated sleep-onset rapid eye movement (REM). The findings revealed a 35% prevalence of newly diagnosed obstructive sleep apnea in patients with fatigue stemmed from their COVID-19 infection.

Reports of the prevalence of [obstructed sleep apnea] in the general population vary, but range between 9% and 38% for mild to severe cases, and between 6% and 17% for only moderate to severe cases, the investigators wrote. The percentage of all [obstructed sleep apnea] cases observed in the present study was therefore in the upper range, and the percentage of moderate to severe cases was slightly higher than reports in the general population.

The investigators concluded by stating the treatment of obstructive sleep apnea with CPAP improved daytime sleepiness.

An improvement in fatigue was reported in these two patients after initiation of automatic positive airway pressure therapy, the investigators wrote. In line with these results, CPAP treatment led to discontinuation of daytime symptoms in the 50% of patients with [obstructive sleep apnea] who agreed to and tolerated CPAP treatment in our study, supporting our suggestion of [obstructed sleep apnea] being a treatable cause of fatigue and daytime sleepiness in patients with post-COVID syndrome.

References

Continue reading here:

Post-COVID-19 Sleepiness Could be Undiagnosed Obstructive ... - MD Magazine

Crisis clubs: What we learned debt, losses and the impact of Covid-19 – The Athletic

November 25, 2023

Over the past week, The Athletic has delved into the financial health of five European clubs Everton, Barcelona, Inter Milan, Hertha Berlin and Lyon to explore how they ran up such substantial debt or losses and the challenges they face going forward.

So what have we learned?

These are all very different clubs of varying sizes in five different countries, some are already part of a multi-club model and one (Everton) want to be, and the majority have recently come under new ownership. They each have their internal problems but there is a common external factor: Covid-19 hit them hard.

When football was paused because of the pandemic in March 2020 and then played in empty or partially-closed stadiums for over a year, our crisis clubs were not sufficiently equipped to cope.

As our Matt Slater explained on The Athletic Football Podcast, Covid-19 was an external shock to these businesses and its all about what sort of state you were in as you went into that shock. What was your plan B? What was your plan C? Was there any plan at all?

The Athletics Crisis clubs series:

Evertons former chief executive Denise Barrett-Baxendale said losses of at least 170million are attributed to Covid-19, with further market analysis indicating that figure could be as much as 50million higher.

But in handing Everton a 10-point deduction last week for breaching the Premier Leagues financial rules, an independent commission was not impressed by the clubs attempts to use the impact of Covid-19 on the transfer market as a mitigating factor. The position that Everton finds itself in is of its own making, the commissions verdict said.

While the pandemic hurt every football club, it almost killed Barcelona.

Being forced to close the gates at their Camp Nou home deprived the club of the largest matchday revenues in Spain, as well as income from their museum and stadium tour. And all that footfall usually meant they sold lots of merchandise, too.

The company which owns Inter took out a loan at 12 per cent interest from U.S. asset management firm Oaktree Capital in 2021 to keep its investment breathing when Covid-19 threatened to take the club under. That now stands at 329million (287m). While not all of it has been drawn down, the loan must either be repaid or refinanced, or the club must be sold otherwise, Oaktree can turn the outstanding debt into equity and repossess it.

Germanys Bundesliga was the first major league to restart worldwide after that first Covid-19 lockdown, in May 2020, but Hertha had just taken on debt to buy back shares they had sold to KKR, a U.S. private equity group, so they could sell again to Lars Windhorst, a London-based financier. What was supposed to be a transformative investment amounted to very little and didnt really change the equation. And if anything, down the line, it made it harder for Hertha to recover financially.

And while it wasnt Lyons fault that French football was particularly battered by Covid-19 and things got even worse when Ligue 1s broadcaster partner Mediapro stopped paying instalments on its 780million annual TV rights deal they were left reliant on successful player trading to make money. And they didnt do particularly well at that.

All these clubs entered the pandemic in bad shape. They were already stretched and, yes, there was also a bit of bad luck for some of them, but when the crisis of Covid-19 came along, it hurt them all in different ways for different reasons.

We hope youve enjoyed the series, both the written pieces and our podcasts.

Thanks for reading, listening and commenting it means a lot.

(Top photos: Getty Images; design: Sam Richardson)

More:

Crisis clubs: What we learned debt, losses and the impact of Covid-19 - The Athletic

Page 65«..1020..64656667..7080..»